Envisagenics closes USD2.35m seed financing round
Envisagenics, a biotechnology company that applies Artificial Intelligence to the genetic sequence of patients to discover new therapies, has raised USD2.35 million in a seed funding round. The investors include Third Kind Venture Capital (3KVC), Cosine, LLC (NYC biotech investors), Dolby Family Ventures, Dynamk Capital, NY Empire State Development (ESD),
